| CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cells M Braun, AR Aguilera, A Sundarrajan, D Corvino, K Stannard, S Krumeich, ... Immunity 53 (4), 805-823. e15, 2020 | 98 | 2020 |
| Roles of the RANKL–RANK axis in antitumour immunity—implications for therapy E Ahern, MJ Smyth, WC Dougall, MWL Teng Nature Reviews Clinical Oncology 15 (11), 676-693, 2018 | 97 | 2018 |
| RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer E Ahern, H Harjunpää, JS O'Donnell, S Allen, WC Dougall, MWL Teng, ... Oncoimmunology 7 (6), e1431088, 2018 | 88 | 2018 |
| Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis A Young, SF Ngiow, J Madore, J Reinhardt, J Landsberg, A Chitsazan, ... Cancer Research 77 (17), 4684-4696, 2017 | 87 | 2017 |
| Co-administration of RANKL and CTLA4 antibodies enhances lymphocyte-mediated antitumor immunity in mice E Ahern, H Harjunpää, D Barkauskas, S Allen, K Takeda, H Yagita, ... Clinical Cancer Research 23 (19), 5789-5801, 2017 | 81 | 2017 |
| Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma A Lepletier, J Madore, JS O'Donnell, RL Johnston, XY Li, E McDonald, ... Clinical Cancer Research 26 (14), 3671-3681, 2020 | 71 | 2020 |
| An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer A Liede, RK Hernandez, SW Wade, R Bo, NC Nussbaum, E Ahern, ... Oncoimmunology 7 (12), e1480301, 2018 | 56 | 2018 |
| An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer. A Liede, RK Hernandez, SW Wade, R Bo, E Ahern, WC Dougall, ... Journal of Clinical Oncology 36 (15_suppl), e21001-e21001, 2018 | 56 | 2018 |
| Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time? E Ahern, BJ Solomon, R Hui, N Pavlakis, K O'Byrne, BGM Hughes Journal for immunotherapy of cancer 9 (6), 2021 | 50 | 2021 |
| Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis H Harjunpää, SJ Blake, E Ahern, S Allen, J Liu, J Yan, V Lutzky, K Takeda, ... Oncoimmunology 7 (7), e1445949, 2018 | 45 | 2018 |
| Respiratory Aerosol Emissions from Vocalization: Age and Sex Differences Are Explained by Volume and Exhaled CO2 N Good, KM Fedak, D Goble, A Keisling, C L’Orange, E Morton, R Phillips, ... Environmental Science & Technology Letters 8 (12), 1071-1076, 2021 | 42 | 2021 |
| Profiling vaccine believers and skeptics in nurses: A latent profile analysis CLK Leung, KK Li, VWI Wei, A Tang, SYS Wong, SS Lee, KO Kwok International journal of nursing studies 126, 104142, 2022 | 28 | 2022 |
| Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a … E Ahern, A Cubitt, E Ballard, MWL Teng, WC Dougall, MJ Smyth, ... Trials 20, 1-9, 2019 | 24 | 2019 |
| PET imaging quantifying 68Ga-PSMA-11 uptake in metastatic colorectal cancer TJ Cuda, AD Riddell, C Liu, VL Whitehall, J Borowsky, DK Wyld, ... Journal of Nuclear Medicine 61 (11), 1576-1579, 2020 | 18 | 2020 |
| Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication WJ Tu, RD McCuaig, M Melino, DJ Rawle, TT Le, K Yan, A Suhrbier, ... Cell Discovery 7 (1), 37, 2021 | 14 | 2021 |
| Retrospective analysis of hospital admissions due to immune checkpoint inhibitor‐induced immune‐related adverse events (irAE) E Ahern, MJ Allen, A Schmidt, Z Lwin, BGM Hughes Asia‐Pacific Journal of Clinical Oncology 17 (2), e109-e116, 2021 | 11 | 2021 |
| COVID-19 and the cancer care workforce: from doctors to ancillary staff H Gasper, E Ahern, N Roberts, B Chan, Z Lwin, MCCCQ Research Seminars in Oncology 47 (5), 309-311, 2020 | 10 | 2020 |
| Impact of sarcopenia and myosteatosis on survival outcomes for patients with head and neck cancer undergoing curative-intent treatment E Ahern, TE Brown, L Campbell, BGM Hughes, M Banks, CY Lin, ... British Journal of Nutrition 129 (3), 406-415, 2023 | 9 | 2023 |
| Trends in epidemiology, treatment and molecular testing of metastatic colorectal cancer in a real‐world multi‐institution cohort study A Kuchel, E Ahern, S Collins, V Whitehall, S Okano, A Pelecanos, D Wyld, ... Asia‐Pacific Journal of Clinical Oncology 17 (1), 84-93, 2021 | 8 | 2021 |
| 663P Safety and preliminary efficacy of the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC C Rojas, I Lugowska, R Juergens, A Sacher, S Weindler, MAN Sendur, ... Annals of Oncology 34, S466-S467, 2023 | 7 | 2023 |
Mark J. SmythQIMR Berghofer在 qimrberghofer.edu.au 的电子邮件经过验证
